We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Reformulated Influenza Rapid Test Made Available

By LabMedica International staff writers
Posted on 19 Mar 2019
Influenza is a viral infection of the upper respiratory system, which includes the nose, bronchial tubes, and lungs. Influenza can make people of any age ill. Although most people, including children, are ill with influenza for less than a week, some have a much more serious illness and may need to be hospitalized. Influenza may also lead to pneumonia or death.

Influenza types A and B are responsible for epidemics of respiratory illness that occur almost every winter and often lead to increased rates of hospitalization and death. Public health efforts to control the impact of influenza focus on types A and B. Influenza viruses continually mutate, which helps the virus to evade the immune system of both children and adults.

Image: The BinaxNOW Influenza A & B Card 2 and Digival reader (Photo courtesy of Abbott).
Image: The BinaxNOW Influenza A & B Card 2 and Digival reader (Photo courtesy of Abbott).

An in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab samples have now been made available. The reformulated test has been granted waived status under the Clinical Laboratory Improvements Amendments by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) for use with a diagnostic reader, for the rapid detection of influenza virus.

The BinaxNOW Influenza A & B Card 2 (Abbott, Chicago, IL, USA) is available for use in hospital laboratories, emergency rooms, physician offices, walk-in clinics and urgent care centers throughout the USA. The Digival reader accurately reads and interprets BinaxNOW Influenza A & B Card 2 tests in seconds, delivering automated, objective results in a broad range of healthcare settings.

Sharon J. Bracken, MBA, senior vice president of Abbott’s rapid diagnostics division, said, “This flu season, healthcare providers need objective tests that can provide fast, accurate results to determine the best course of care for patients. The BinaxNOW Influenza A & B Card 2 adds to our strong portfolio of rapid flu tests by providing rapid and easy diagnosis, while Digival enhances healthcare providers’ confidence in results by reducing user subjectivity.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest Technology News

New Diagnostic System Achieves PCR Testing Accuracy

DNA Biosensor Enables Early Diagnosis of Cervical Cancer

Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples